Yes, quite right. That's the trouble with having too many tabs open at the same time and so many CHM trials on the go! Thanks, again, reon.
So, we have yet to receive any news regarding CORE-NK with Vactosertib for bowel cancer? But have the CR at 28-days in AML in combo with the other novel drugs.
MDA are being tight-lipped with the ADVENT-AML progress (other than its safe to progress to the next stage). I guess they have nothing to gain by unveiling efficacy signals (if any) beyond what is expected for the SOC therapies.
CHM Price at posting:
1.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)